Author

R. Quevedo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:chromatin & epigenetic regulation· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

T. L. McGaha· 2 shared A. P. McGuigan· 1 shared B. Haibe-Kains· 1 shared C. A. Simmons· 1 shared C. H. Arrowsmith· 1 shared D. Cescon· 1 shared E. D'Arcangelo· 1 shared F. Sun· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

T. L. McGaha

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Dabrafenib alters MDSC differentiation and function by activation of GCN2

M. T. Ciudad, R. Quevedo, S. Lamorte, R. Jin, N. Nzirorera, M. Koritzinsky, T. L. McGaha

This study shows that dabrafenib inhibits PMN-MDSC differentiation via GCN2 activation, altering their function and reducing their suppressive activity in tumors.

bioRxiv · Aug 9, 2023Immunology

EHMT2/G9a-Inhibition Reprograms Cancer-Associated Fibroblasts (CAFs) to a More Differentiated, Less Proliferative and Invasive State

N. C. Wu, R. Quevedo, M. Nurse, K. Hezaveh, H. Liu, F. Sun, J. Muffat, Y. Sun, C. A. Simmons, T. L. McGaha, P. Prinos, C. H. Arrowsmith, L. Ailles, E. D'Arcangelo, A. P. McGuigan

This study identifies EHMT2 as a key regulator of CAF hyperproliferation and pro-invasive behavior, showing its inhibition reprograms CAFs to a less aggressive state.

bioRxiv · Jul 17, 2023 · PreprintCancer Biology

Non-coding mutations reveal cancer driver cistromes in luminal breast cancer

S. El Ghamrasni, R. Quevedo, J. R. Hawley, P. Mazrooei, Y. Hanna, I. Cirlan, H. Zhu, J. P. Bruce, L. E. Oldfield, S. Y. C. Yang, P. Guilhamon, J. Reimand, D. Cescon, S. J. Done, M. Lupien, T. Pugh

The paper identifies cancer driver cistromes in luminal breast cancer by analyzing non-coding mutations in cis-regulatory elements from ATAC-seq data and integrating them with somatic mutations.

bioRxiv · May 29, 2021Cancer Biology

Karyotypic divergence confounds cellular phenotypes in large pharmacogenomic studies

R. Quevedo, N. El-Hachem, P. Smirnov, Z. Safikhani, T. J. Pugh, B. Haibe-Kains

This study identifies discordances in genotypic and karyotypic profiles across pharmacogenomic datasets, highlighting the impact of copy-number variants on drug response and the need for verification of cell line profiles.

bioRxiv · Mar 11, 2019 · PreprintCancer Biology